The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
12 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,209,336 in first-year total cost, median $300,000.
Most frequent study sections
- Special Emphasis Panel[ZTR1 CI-5 (01)]3
- Special Emphasis Panel[ZTR1 SBIR-5 (01)]3
- Special Emphasis Panel[ZTR1 CI-2 (01)]2
- Special Emphasis Panel[ZTR1 CI-3 (01)]2
- Special Emphasis Panel[ZTR1 SBIR-3 (01)]2
Most frequent institutions
- DTX PHARMA, LLC2
- SIVEC BIOTECHNOLOGIES, LLC2
- APTITUDE MEDICAL SYSTEMS, INC.1
- CAROGEN CORPORATION1
- FERROLOGIX, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform2R44AI140243-02 | LINKE, LYNDSEY | SIVEC BIOTECHNOLOGIES, LLC, CO | $1,028,842 | ZTR1 |
| 2020 | VLVs as platform for nucleic acid-based delivery:Combining therapeutic vaccine with shRNA-mediated PD-L1 blockade for the treatment of chronic hepatitis B virus1R43AI149798-01A1 | NAKAAR, VALERIAN | CAROGEN CORPORATION, CT | $300,000 | ZTR1 |
| 2019 | High Throughput Magnetic Assisted Transfection Platform for Autologous Hematopoietic Stem Cell Therapies1R43TR002701-01 | MURRAY, COLEMAN | FERROLOGIX, INC., CA | $323,578 | ZTR1 |
| 2019 | Systemic Characterization of Novel Lipidated siRNA Conjugates1R43TR002791-01 | SUCKOW, ARTHUR THOMAS | DTX PHARMA, LLC, CA | $321,555 | ZTR1 |
| 2019 | Development of Conjugated Oligonucleotide Therapeutics for Neuronal Disease1R43TR002702-01A1 | SUCKOW, ARTHUR THOMAS | DTX PHARMA, LLC, CA | $301,212 | ZTR1 |
| 2019 | Ultrasound as a platform for formulation and sequence-independent delivery of nucleic acids1R43TR002559-01A1 | SCHOELLHAMMER, CARL MAGNUS | SUONO BIO, INC., MA | $263,419 | ZTR1 |
| 2018 | Design and Optimization of Clinical Gene Gun for Delivery of Nucleic Acid Vaccines1R43AI140784-01 | FULLER, DEBORAH H.MUNSON, PAUL VENESS | ORLANCE, INC., WA | $300,000 | ZTR1 |
| 2018 | Topical delivery of therapeutic aptamers1R43EB026362-01A1 | GONG, QIANG | APTITUDE MEDICAL SYSTEMS, INC., CA | $293,239 | ZTR1 |
| 2018 | A versatile transkingdom platform for therapeutic nucleic acid delivery to mucosal epithelial tissues1R43AI140243-01A1 | LINKE, LYNDSEY | SIVEC BIOTECHNOLOGIES, LLC, CO | $293,142 | ZTR1 |
| 2018 | Droplette: A Platform Technology to Deliver Nucleic Acid Therapeutics Deep into Tissue for the Treatment of Epidermolysis Bullosa and Other Genetic Diseases1R43EB026363-01 | QUEK, B. LINSRINIVAS, RATHI | NOVOPYXIS, INC., MA | $248,585 | ZTR1 |
| 2018 | Platform Delivery Technology for Plasmid DNA Therapeutics1R43TR002414-01 | JIANG, DAHAI | LIPOGENE COMPANY, INC., CA | $210,834 | ZTR1 |
| 2017 | Platform Delivery Technology for Nucleic Acid Therapeutics to Promote Wound Healing1R43TR002225-01 | WHITE, ALEKSANDR | LAYERBIO, INC., MA | $324,930 | ZTR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.